Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on January 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 50,000 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule5635(c)(4).
Related news for (SPRO)
- Today’s Top Performers: MoBot’s Market Review 05/30/25 09:00 AM
- Biotech Today: From Sustainable Biomaterials to First-in-Class Therapies
- Today’s Top Performers: MoBot’s Market Review 05/28/25 07:00 AM
- Spero Therapeutics and GSK Announce Early Completion of Phase 3 PIVOT-PO Trial for Oral Antibiotic Tebipenem HBr Based on Positive Efficacy Results
- Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee